{"title":"替索单抗维多汀对复发性宫颈癌有效","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00929-4","DOIUrl":null,"url":null,"abstract":"<p>Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited treatment options available. Now, data from the phase III innovaTV 301 trial demonstrate the efficacy of the tissue factor-targeted antibody–drug conjugate tisotumab vedotin in this setting.</p><p>A total of 502 patients with advanced-stage and/or metastatic cervical cancer who previously received 1 (62.8%) or 2 (36.8%) lines of therapy were randomly assigned (1:1) to receive tisotumab vedotin versus investigator’s choice of chemotherapy (including topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed). Overall survival (OS) was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tisotumab vedotin effective in recurrent cervical cancer\",\"authors\":\"Peter Sidaway\",\"doi\":\"10.1038/s41571-024-00929-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited treatment options available. Now, data from the phase III innovaTV 301 trial demonstrate the efficacy of the tissue factor-targeted antibody–drug conjugate tisotumab vedotin in this setting.</p><p>A total of 502 patients with advanced-stage and/or metastatic cervical cancer who previously received 1 (62.8%) or 2 (36.8%) lines of therapy were randomly assigned (1:1) to receive tisotumab vedotin versus investigator’s choice of chemotherapy (including topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed). Overall survival (OS) was the primary end point.</p>\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2024-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-024-00929-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00929-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
复发性晚期和/或转移性宫颈癌患者的预后通常较差,可供选择的治疗方案有限。现在,innovaTV 301 III 期试验的数据证明了组织因子靶向抗体药物共轭物 tisotumab vedotin 在这种情况下的疗效。研究人员随机分配(1:1)502名既往接受过1线(62.8%)或2线(36.8%)治疗的晚期和/或转移性宫颈癌患者接受替索单抗维多汀与研究者选择的化疗(包括托泊替康、维诺雷滨、吉西他滨、伊立替康或培美曲塞)。总生存期(OS)是主要终点。
Tisotumab vedotin effective in recurrent cervical cancer
Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited treatment options available. Now, data from the phase III innovaTV 301 trial demonstrate the efficacy of the tissue factor-targeted antibody–drug conjugate tisotumab vedotin in this setting.
A total of 502 patients with advanced-stage and/or metastatic cervical cancer who previously received 1 (62.8%) or 2 (36.8%) lines of therapy were randomly assigned (1:1) to receive tisotumab vedotin versus investigator’s choice of chemotherapy (including topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed). Overall survival (OS) was the primary end point.
期刊介绍:
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.